Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01380743 · ClinicalTrials.gov registry record · Phase 2

Drug-drug Interaction Study

A Phase 2 study of Pompe Disease, sponsored by Amicus Therapeutics.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
15
Study locations

NCT01380743 is a Phase 2 study of Pompe Disease that has completed, run by Amicus Therapeutics. The registered enrollment target is 25 participants, below the 231-participant average among 14 other Pompe Disease trials with a reported enrollment target (89% lower). The trial reports 15 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01380743, a Phase 2 study of Pompe Disease, has completed, sponsored by Amicus Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
15
Study locations

Study Summary

This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.

Conditions Studied

Pompe Disease

Interventions

  • DRUG duvoglustat
  • DRUG rhGAA

Study Locations (15)

Arizona

  • - Phoenix
  • - Scottsdale

Other

  • - Paris
  • - Salford

California

  • - Orange

Florida

  • - Gainesville

Georgia

  • - Decatur

Kansas

  • - Kansas City

Montana

  • - Great Falls

North Carolina

  • - Durham

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2011-10-31
Est. Completion 2013-01-04
Phase Phase 2

Sponsor

Amicus Therapeutics

34 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01380743

The ClinicalTrials.gov registry entry for NCT01380743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 14 other Pompe Disease trials with a reported enrollment target (89% lower). The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pompe Disease appearing as the primary indexed condition, and to 2 interventions - of which duvoglustat is the first listed.

NCT01380743 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Other, California.

Frequently Asked Questions

What is clinical trial NCT01380743 about?

NCT01380743 is a clinical study titled "Drug-drug Interaction Study". This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.

What is the current status of trial NCT01380743?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-10-31. Estimated completion is 2013-01-04.

What conditions does trial NCT01380743 study?

This clinical trial studies the following conditions: Pompe Disease.

What interventions are being tested in trial NCT01380743?

The interventions under investigation include: duvoglustat (DRUG), rhGAA (DRUG).

Who is sponsoring clinical trial NCT01380743?

This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01380743 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pompe Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pompe Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.